DELCATH SYSTEMS, INC.
Delcath is an interventional oncology company focused on treating cancers that originate in or spread to the liver. It operates as one segment and markets two products based on its Hepatic Delivery System. In the United States, HEPZATO KIT combines melphalan with the delivery system and is FDA-approved for certain adults with uveal melanoma that has spread to the liver. In Europe, the device-only system is sold as CHEMOSAT for use with melphalan in liver-directed procedures. The products are designed for percutaneous hepatic perfusion, which delivers chemotherapy to the liver while filtering hepatic venous blood. Delcath earns money from commercial sales of HEPZATO KIT and CHEMOSAT; cancer centers use the products and seek reimbursement for the product and procedure from payors. Delcath also conducts clinical development of the products for other liver cancer indications. Its corporate offices are in Queensbury, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $DCTH in the last 30 days.
See all $DCTH insider activity →HC Wainwright & Co. kept its Buy rating on Delcath Systems and increased its price target to $36 from $32, suggesting a 77.6% upside from the Nov 9 close of $20.27.
Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.
DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Third Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $115 million to $117 million Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – November 9, 2026, Delcath Systems, Inc. (Nasdaq: DCT
Over the past 7 days, AlphAI's AI scored 18 news stories mentioning DCTH (DELCATH SYSTEMS, INC.). Coverage has skewed bullish: 17 bullish, 1 neutral, and 0 bearish.
Recent DCTH coverage spans earnings, financial news and technology.
Analyst upgrade suggests potential upside and may attract buying interest.
Raised guidance plus improved profitability metrics can support continued multiple expansion and momentum trading.
Positive earnings beat and raised guidance suggest upside pressure.
Earnings beat with significant top‑line growth and profitability improvement.
Positive trial outcomes suggest higher efficacy of the CHEMOSAT system, likely boosting investor sentiment.
AlphAI scores every news story that mentions DCTH with an AI model for sentiment and relevance, and aggregates insider trades from DELCATH SYSTEMS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. kept its Buy rating on Delcath Systems and increased its price target to $36 from $32, suggesting a 77.6% upside from the Nov 9 close of $20.27.
Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.
DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Third Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $115 million to $117 million Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – November 9, 2026, Delcath Systems, Inc. (Nasdaq: DCT
Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 70% YoY from $20.6M, with net income of $7.0M versus $0.8M, and adjusted EBITDA of $11.5M versus $5.3M. Growth attributed to HEPZATO sales and clinical development.
Delcath Systems (DCTH) announced presentations at ESMO Congress 2026, including updates on its Phase 2 trials for metastatic colorectal and breast cancer. Independent data on its CHEMOSAT system for liver-dominant metastatic uveal melanoma showed a 66.7% objective response rate and 28-month median overall survival. The company focuses on liver cancer treatments with its HEPZATO KIT and CHEMOSAT systems.
An independent analysis of 12 patients with liver-metastatic uveal melanoma treated with melphalan hepatic delivery (PHP) and ipilimumab/nivolumab reported a 66.7% response rate and 75% disease control rate. The median overall survival was 28 months. Delcath Systems, Inc. is presenting clinical trial updates at ESMO Congress 2026, including data on its HEPZATO KIT and CHEMOSAT systems for liver-directed chemotherapy.
Delcath Systems (DCTH) reported Q2 revenue of $29.1M, up from $24.2M YoY, driven by its HEPZATO KIT and CHEMOSAT devices. The company raised its 2026 revenue guidance to $104M-$108M. However, expenses rose, with R&D and SG&A increasing, leading to flat net income. Delcath has $95.9M in cash and no debt, and is expanding into new indications.
DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven
Delcath Systems (Nasdaq: DCTH) said the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO plus standard of care versus standard of care alone for liver-dominant HER2-negative metastatic breast cancer. The randomized study will enroll about 90 patients at 20+ sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.
Delcath Systems announced new data from a retrospective analysis on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT Hepatic Delivery System for liver-dominant metastatic breast cancer. The data, presented at the ESMO Breast Cancer Congress 2026, showed hepatic partial response in 60% of evaluable patients and highlighted safety considerations like blood transfusions and transient bone marrow suppression. This real-world evidence supports further evaluation of HEPZATO KIT and CHEMOSAT in this heavily pretreated patient population.
